🇺🇸 ALXN1210 in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 5
Most-reported reactions
- Arthritis Bacterial — 1 report (20%)
- Dyspnoea Exertional — 1 report (20%)
- Fracture — 1 report (20%)
- Granuloma Skin — 1 report (20%)
- Varicella Zoster Virus Infection — 1 report (20%)
Other Rare Disease approved in United States
Frequently asked questions
Is ALXN1210 approved in United States?
ALXN1210 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for ALXN1210 in United States?
Alexion Pharmaceuticals, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.